# Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

> **NCT00790816** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 500 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Lapatinib in combination with an anti-cancer agent
- **DRUG:** Lapatinib
- **DRUG:** Lapatinib in combination with an anti-cancer agent as specified by parent protocol

## Key facts

- **NCT ID:** NCT00790816
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2016-08-19
- **Final completion:** 2016-08-19
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2018-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790816, "Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00790816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*